FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-02-26

Price

$14.33

-0.07%

Score13.5Top Tier

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.0xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is currently a 'High Score' conviction play, functioning as a Merger Arbitrage vehicle rather than a traditional growth stock. The company is in a definitive agreement to be acquired by BioMarin (BMRN) for $14.50 per share in cash, explaining the 'Steady Climb' and 'Quiet Storm' signals as the stock remains pinned to the deal price with compressed volatility. The 'Alpha Male' signal in this context represents 'Defensive Alpha'—while the broader market rotates and digests Nvidia's earnings, FOLD offers a secured, non-correlated return profile anchored by the pending Q2 2026 closing.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

Arbitrage Conviction: The stock is trading at $14.33, offering a ~1.2% absolute spread to the $14.50 cash takeout price (approx. 4-5% annualized yield if closed by Q2).
Signal Interpretation: The 'Alpha Male' signal is a false positive for breakout momentum but a true positive for relative strength; FOLD acts as a capital preservation tool during market rotation.
Execution Risk: The primary risk is regulatory (FTC/HSR), though the recent Q4 earnings report (Feb 20) reiterated the deal is on track with no new hurdles.

← Back to 2026-02-26 View Full FOLD History →Yahoo Finance &nearr;